Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Regs On Experimental Drug Access May Be Loosened After Court Loss

Executive Summary

FDA's ongoing development of rules for expanded access programs will likely take a broader approach after the agency's current standards were questioned by an appeals court

You may also be interested in...



FDA Can Expand Access To Experimental Drugs, Without Compromising Trials

FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb

Outcome Of Abigail Alliance Case May Be Moot Due To Marketplace Issues

Regardless of whether a federal appeals court determines that patients have a fundamental right to experimental therapy, it appears a host of potential problems in the marketplace will stymie increased access to such therapies in practice

FDA Can Expand Access To Experimental Drugs, Without Compromising Trials

FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb

Related Content

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel